Mobocertinib
Mobocertinib (TAK-788) is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib can be used in NSCLC research[1][2].
Product Specifications
CAS Number
1847461-43-1
Product Name Alternative
TAK-788; AP32788
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/mobocertinib.html
Purity
99.09
Solubility
DMSO : 25 mg/mL (ultrasonic; warming; heat to 80°C)
Smiles
O=C(C1=CN=C(NC2=CC(NC(C=C)=O)=C(N(CCN(C)C)C)C=C2OC)N=C1C3=CN(C)C4=C3C=CC=C4)OC(C)C
Molecular Formula
C32H39N7O4
Molecular Weight
585.70
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
EGFR/ErbB1/HER1; ErbB2/HER2
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD14 (Monocyte / Macrophage Marker) (LPSR/2385), CF405S conjugate, 0.1mg/mL
